Sanofi's Dupixent To Keep Soaring Despite NICE Blip
HTA Body Rejects Blockbuster For Severe Asthma
Executive Summary
NICE is not recommending Dupixent for severe asthma just yet but Sanofi remains confident of hitting its sales target of €10bn a year.